New mechanisms of CCR5-Δ32 carriers' advantage – Impact on progenitor cells and renal function

Skrzypkowska, Maria; Słomiński, Bartosz; Ryba-Stanisławowska, Monika; Ławrynowicz, Urszula; Gutknecht, Piotr; Siebert, Janusz

doi:10.1016/j.biocel.2019.01.006

Cited by 1 publication

(1 citation statement)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Mlynarski et al (2005) showed that the CCR5-D32 mutation increased the risk of kidney disease in men with type 1 diabetes; however, this outcome is contrary to that of Prasad et al (2007) who found that CCR5-D32 was not related to nephropathic type 2 diabetes patients. Skrzypkowska et al (2019) even indicated that 32 allele-bearing individuals exhibit more beneficial values of kidney function parameters. Specifically, the wt/Δ32 and Δ32/Δ32 carriers exhibited a higher number of CD34 + VEGFR 2+ and CD34 + VEGFR 2+ c-Kit + cells than that in the wild type counterparts.…”

Section: Hyperglycemiamentioning

confidence: 99%

Chemokine Receptor 5, a Double-Edged Sword in Metabolic Syndrome and Cardiovascular Disease

et al. 2020

View full text Add to dashboard Cite

The key characteristic of cardiovascular disease (CVD) is endothelial dysfunction, which is likely the consequence of inflammation. It is well demonstrated that chemokines and their receptors play a crucial role in regulating inflammatory responses, and recently, much attention has been paid to chemokine receptor 5 (CCR5) and its ligands. For example, CCR5 aggravates the inflammatory response in adipose tissue by regulating macrophage recruitment and M1/M2 phenotype switch, thus causing insulin resistance and obesity. Inhibition of CCR5 expression reduces the aggregation of pro-atherogenic cytokines to the site of arterial injury. However, targeting CCR5 is not always effective, and emerging evidence has shown that CCR5 facilitates progenitor cell recruitment and promotes vascular endothelial cell repair. In this paper, we provide recent insights into the role of CCR5 and its ligands in metabolic syndrome as related to cardiovascular disease and the opportunities and roadblocks in targeting CCR5 and its ligands.

show abstract

Section: Hyperglycemiamentioning

confidence: 99%